SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

RAD: 11-177191- -6 **FECHA**: 2013-06-26 18:40:27
DEP: 2020 DIRECCION DE NUEVAS CREACIONES **EVE:** 378 FASE NACIONAL INCLUIDO CAPITULO I
TRA: 11 PCT-PATENTE DE INVENCION CAPITULOS I Y II **FOLIOS**: 5
ACT: 519 PRESENTACION

DIRECCIÓN DE NUEVAS CREACIONES

2020
Bogotá, D.C.,

Abogado(a)/Señor(a)
CARLOS REINALDO OLARTE GARCIA

Asunto: Radicación: 11-177191- -6
Trámite: 11
Evento: 378
Actuación: 519
Oficio: 11197
Folios: 5

Patente de Invención	X			Patente de Modelo de Utilidad	
Vía Nacional					
Vía PCT (Fase Nacional)	X	Capítulo I	X	Capítulo II	
No. Solicitud Internacional	PCT/US2010/039510				
Fecha de Presentación Internacional	22/06/2010				

Como resultado del examen de fondo realizado, con fundamento en el Artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, se comunica:

1. Documentos estudiados

Descripción:	Folios 94 a 186	22/Diciembre/2011
Reivindicaciones:	Folios 237 a 245	22/Diciembre/2011
Dibujos:	Folios 325 a 353	22/Diciembre/2011
Secuencias:	Folios 261 a 324	22/Diciembre/2011
Prioridad:	US 61 219 134	22/Junio/2009

2. Análisis de la Prioridad

Se acepta la reivindicación de prioridad porque ésta solicitud fue presentada dentro del plazo establecido (Art. 9 D 486) y su contenido técnico corresponde con el de la prioridad reivindicada.

3. Objeto de la invención

De acuerdo con lo establecido en el numeral 1.2.2.2 del capitulo primero del Título 10 de la Circular Única para efectos del examen de patentabilidad, se tendrá en cuenta la tasa pagada por el solicitante al momento de comenzar el examen para las reivindicaciones adicionales; esto es que cuando la solicitud contenga más de diez (10) reivindicaciones y no se haya pagado la tasa complementaria, sólo se estudiarán las cubiertas por la tasa pagada. Para la presente solicitud se estudió todo el capítulo completo, aún cuando no se realizó el pago de las reivindicaciones adicionales. Se debe realizar el pago de la tasa faltante proceder con el proceso.

Título de la solicitud: "Composiciones inmunogénicas de antígenos de *Staphylococcus aureus* referencia cruzada a las solicitudes relacionadas"

El problema planteado en esta solicitud consiste en la necesidad de compocisiones inmunogénicas útiles para su uso en vacunas como medio para tratar una infección por estafilococos y enfermedades asociadas.

Para resolver este problema técnico la solicitud en estudio proporciona una composición inmunogénica que comprende al menos tres componentes que se seleccionan del grupo que consiste en: un polipéptido de factor de aglutinación A (ClfA) de *S. aureus* aislado, un polipéptido de factor de coagulación B (ClfB) de *S. aureus* aislado, una proteína de MntC de *S. aureus* aislada, un polisacárido capsular de *S. aureus* aislado de tipo 5 conjugado con una proteína de portador, y un polisacárido capsular de *S. aureus* aislado de tipo 8 conjugado con una proteína portador.

El objeto de la presente solicitud se relaciona con la Clasificación Internacional de Patentes (CIP): A61K 39/085.

4. Excepción a la Patentabilidad (Art 20 D 486 literal (d))

Los métodos de tratamiento en humanos o animales están exentos de patentabilidad, por lo tanto, el objeto de las reivindicaciones 76 – 90 no es patentable de acuerdo con el Art citado.

5. De la solicitud de patente

Reivindicaciones (Art 30 D 486, Art 22 PCT)

El capítulo reivindicatorio completo carece de claridad y concisión, por cuanto:

1) Los polipéptidos o proteínas de la composición inmunogénica de las reivindicaciones 1 – 4, 23 – 27, 43 – 46, 57 – 59, 71 - 72 deben estar definidos por su estructura completa, es decir, por la secuencia de aminoácidos, y además deben estar identificados por un número de identificación SEQ ID Nº y referenciadas en el listado de secuencias;

2) De igual forma, los dominios de unión a fibrinógeno deben estar definidos por su estructura y se debe indicar la localización en la secuencia de la unión (Reivindicaciones 5 – 8, 28 – 31, 47 – 50 y 54 - 56);

3) Las reivindicaciones 9, 10, 11, 51 - 53 carecen de claridad puesto que reclaman sustituciones de aminoácidos sin indicar la secuencia de aminoácidos donde se llevarán a cabo dichas modificaciones;

4) Las reivindicaciones 12, 32 y 60 son inadmisibles puesto que reclaman polipéptidos a partir de su forma de reproducción. Un producto debe ser reivindicado por las características esenciales;

5) El uso de rangos para describir el peso molecular y el grado de O-acetilación de los polisacáridos capsulares carece de concisión y no permite distinguir la materia reclamada del estado de la técnica. Se sugiere usar valores limitativos o específicos para definir las características estructurales de los componentes de la composición reclamada (reivindicaciones 13 - 22, 33 - 42, 61 - 70);

6) El adyuvante y el portador farmacéuticamente aceptable de las reivindicaciones 73 y 74 carece de concisión. Se recuerda a la solicitante que una composición debe estar definida por su estructura en términos de sus elementos esenciales (compuesto activo y excipientes) y sus proporciones;

7) Una reivindicación será independiente cuando defina la materia que se desea proteger sin referencia a otra reivindicación anterior. De acuerdo a esto, se sugiere revisar la reivindicaciones 2, 26, 46 y 59 pues están redactadas a manera de reivindicaciones independientes pero definen variaciones de la materia reclamada en la reivindicación 1.

Descripción (Art 28 D 486)

La descripción no divulga la invención de manera suficientemente completa para que la persona del oficio normalmente versada en la materia pueda ejecutarla (ó reproducirla). Dado que esta solicitud se refiere a secuencias de aminoácidos, polipéptidos y proteínas, deben presentarse el número SEQ ID Nº asociado a cada uno de ellos y referenciarlos en el “Listado de secuencias”.

Se requiere hacer las aclaraciones necesarias.

6. Determinación del Estado de la Técnica

El estado de la técnica se determinó con base en la fecha de presentación de la solicitud de prioridad: 22 de Junio de 2009, y se encontraron los siguientes documentos que anticipan el objeto de esta solicitud:

Ítem	Documento	Título	Fecha de Publicación
D1[1]	WO 2007/113222	“Immunogenic composition”	11/Octubre/2007
D2[2]	Deivanayagam *et al.* 2002	“A novel variant of the immunoglobulin fold in surface adhesins of *Staphylococcus aureus*: crystal structure of the fibrinogen-binding MSCRAMM, clumping factor A”	16/Diciembre/2002

El documento D1 enseña composiciones inmunogénicas que comprenden polisacaridos capsulares tipo 5 y/u 8 de *S. aureus* que tienen entre 30 y 100% de O-acetilación (Resumen).

1 http://www.patentlens.net/patentlens/patents.html?patnums=WO_2007_113222

2 Deivanayagam, C., *etal* 2002. A novel variant of the immunoglobulin fold in surface adhesins of Staphylococcus aureus: crystal structure of the fibrinogen-binding MSCRAMM, clumping factor A. EMBO J. 21(24): 6660–6672

El documento D2 enseña la estructura cristalina de ClfA de *S. aureus* con sustituciones mutagénicas en los residuos Tyr256, Pro336, Tyr338 y Lys389 que resultan en proteínas con afinidad nula o marcadamente reducida a fibrinógeno (Resumen).

7. Examen de Patentabilidad (Art 14 D486)

Novedad (Art 16 D486)

La reivindicación 1 consiste en una composición inmunogénica que comprende al menos tres componentes que se seleccionan del grupo que consiste en: un polipéptido de factor de aglutinación A (ClfA) de *S. aureus* aislado, un polipéptido de factor de coagulación B (ClfB) de *S. aureus* aislado, una proteína de MntC de *S. aureus* aislada, un polisacárido capsular de *S. aureus* aislado de tipo 5 conjugado con una proteína de portador, y un polisacárido capsular de *S. aureus* aislado de tipo 8 conjugado con una proteína portador.

Comparación de las características técnicas esenciales, con las del estado de la técnica:

Características esenciales	D1
una composición inmunogénica que comprende al menos tres componentes que se seleccionan del grupo que consiste en:	una composición inmunogénica que comprende dos o más componentes que se seleccionan de: (Pág. 29 líneas 16 – 23)
un polipéptido de factor de aglutinación A (ClfA) de *S. aureus* aislado,	Un grupo de proteínas extracelulares que incluye a ClfA (Pág. 29 línea 31)
un polipéptido de factor de coagulación B (ClfB) de *S. aureus* aislado,	Un grupo de proteínas extracelulares que incluye a ClfB (Pág. 29 línea 32)
una proteína de MntC de *S. aureus* aislada	Un grupo de proteínas extracelulares que incluye a MntC de S. aureus (Pág. 29 línea 30)
un polisacárido capsular de *S. aureus* aislado de tipo 5 conjugado con una proteína de portador	Un polisacárido tipo 5 capsular de S. aureus (Pág. 5 líneas 1 – 5) conjugado con al menos una proteína transportadora (Pág. 29 líneas 21 y 35)
y un polisacárido capsular de *S. aureus* aislado de tipo 8 conjugado con una proteína portador.	Un polisacárido tipo 8 capsular de S. aureus (Pág. 5 líneas 1 – 5) Conjugado con al menos una proteína transportadora (Pág. 29 líneas 21 y 35)

Las características esenciales de la composición de la reivindicación 1 habían sido divulgadas previamente en el documento D1, el cual enseña una composición farmacéutica con polisacáridos capsulares de *S. aureus* tipo 5 y 8 de peso entre 75 y 400kDa y con un grado de O-acetulación de 30 a 100%, que pueden estar conjugados con al menos una proteína transportadora, y al menos dos proteínas seleccionadas del grupo de proteínas extracelulares que incluye a ClfA, ClfB y MntC (Pág. 29 líneas 16 – 37).

En consecuencia, la reivindicación 1 no es nueva, según lo divulgado en el documento D1.

Las reivindicaciones dependientes 2 – 7, 12 – 30, 32 – 49 y 54 - 75, no mencionan alguna característica que haga nueva a la composición de la reivindicación 1, por lo cual se considera que no son nuevas.

Nivel inventivo (Art18 D486)

La reivindicación 8 consiste en una composición inmunogénica de acuerdo a cualquiera de las reivindicaciones 5, 6 o 7, en la que el dominio de unión a fibrinógeno de ClfA se une a fibrinógeno a un nivel reducido en comparación con la unión que se observa a fibrinógeno con el dominio de unión a fibrinógeno de ClfA nativo.

El documento D1 se considera el estado de la técnica cercano a la invención definida en la reivindicación 8 porque divulga una composición inmunogénica que comprende al

menos dos proteínas dentro de las que se incluye ClfA (Pág. 29 línea 31).

La diferencia entre la invención, definida en la reivindicación 8 y la composición del documento D1 es que este último no define que a la proteína ClfA se une a fibrinógeno un nivel reducido.

El capítulo descriptivo no incluye resultados comparativos entre la proteína ClfA unida a fibrinógeno en un nivel reducido, comparada con la proteína ClfA nativa que soporten la existencia de un efecto sorprendente o inesperado.

Por lo tanto, el problema técnico objetivo que pretende resolver esta invención se puede formular así: "cómo modificar el estado de la técnica del documento D1 para conseguir una proteína ClfA unida a un fibrinógeno a un nivel reducido?"

Sin embargo, una proteína ClfA con una afinidad de unión a fibrinógeno reducida o casi nula ya había sido divulgada previamente en el documento D2, que se refiere a una variante de proteína de superficie celular ClfA de *S. aureus* que está mutada en las posiciones Tyr256, Pro336, Tyr338 y Lys389 que le confieren una unión a fibrinógeno a un nivel reducido (Resumen).

De este modo, la persona del oficio normalmente versada en la materia, incluiría esta característica del documento D2 en la construcción de composiciones inmunogénicas del documento D1 para llegar así al objeto de la reivindicación 8 de la solicitud. Por lo cual, la solución aquí propuesta se considera obvia.

En consecuencia, la reivindicación 8 no cumple con el requisito de nivel inventivo (Art. 18).

Las reivindicaciones 9 – 11, 31, 50 – 53 no aportan características adicionales por lo tanto se consideran sin nivel inventivo.

8. Conclusión

Los requisitos de Patentabilidad de la presente solicitud están afectados así:

Ítem	Documento	Reivindicaciones afectadas	Requisito que afecta
D1	WO 2007/113222	1 – 7, 12 – 30, 32 – 49 y 54 - 75	Novedad
D1	WO 2007/113222	8 – 11, 31, 50 – 53	Nivel inventivo
D2	Deivanayagam *et al.* 2002	8 – 11, 31, 50 – 53	Nivel inventivo

En cumplimiento del artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, se le indica que debe dar respuesta dentro del término de sesenta (60) días contados a partir de la fecha de notificación de la presente comunicación. En caso de no dar respuesta al presente requerimiento, o si a pesar de la respuesta subsistieran los impedimentos para la concesión, se denegará la patente.

Se invita al solicitante se sirva indicar, si así lo considera, su renuncia al término faltante de sesenta (60) días para dar respuesta a este requerimiento y presentarla por escrito.

Finalmente, se le recuerda al solicitante que si como respuesta a este requerimiento llegara a modificar el capítulo reivindicatorio y éste contenga más de diez (10) reivindicaciones, no pagará la tasa de modificación voluntaria pero sí la correspondiente al pago por reivindicación adicional.

Notifíquese el presente oficio conforme a lo dispuesto en el numeral 5.2, literal e), del capítulo quinto del título primero de la Circular Única No. 10 de 2001.

JOSÉ LUIS SALAZAR LÓPEZ
Director de Nuevas Creaciones (c)

El anterior requerimiento fue notificado por fijación en lista, de fecha 2013-07-02

Elaboró: Edna Carolina Bonilla Leon
Revisó: Consuelo Leguizamon Leguizamon

The EMBO Journal Vol. 21 No. 24 pp. 6660–6672, 2002

A novel variant of the immunoglobulin fold in surface adhesins of *Staphylococcus aureus*: crystal structure of the fibrinogen-binding MSCRAMM, clumping factor A

Champion C.S.Deivanayagam[1], Elisabeth R.Wann[2,3], Wei Chen[2], Mike Carson[1], Kanagalaghatta R.Rajashankar[4], Magnus Höök[2] and Sthanam V.L.Narayana[1,5]

[1]Center for Biophysical Sciences and Engineering, School of Optometry, 244 CBSE, 1025 18th Street South, University of Alabama at Birmingham, Birmingham, AL 35294-0005, [2]Institute of Biosciences and Technology, Center for Extracellular Matrix Biology, 2121 West Holcombe Boulevard, Texas A&M University System Health Science Center, Houston, TX 77030-303 and [4]Brookhaven National Laboratory, Building 725A-X9, Upton, NY 119773, USA

[3]Present address: Lexicon Genetics Inc., 8800 Technology Forest Place, The Woodlands, TX 77381, USA

[5]Corresponding author
e-mail: narayana@uab.edu

We report here the crystal structure of the minimal ligand-binding segment of the *Staphylococcus aureus* MSCRAMM, clumping factor A. This fibrinogen-binding segment contains two similarly folded domains. The fold observed is a new variant of the immunoglobulin motif that we have called DE-variant or the DEv-IgG fold. This subgroup includes the ligand-binding domain of the collagen-binding *S.aureus* MSCRAMM CNA, and many other structures previously classified as jelly rolls. Structure predictions suggest that the four fibrinogen-binding *S.aureus* MSCRAMMs identified so far would also contain the same DEv-IgG fold. A systematic docking search using the C-terminal region of the fibrinogen γ-chain as a probe suggested that a hydrophobic pocket formed between the two DEv-IgG domains of the clumping factor as the ligand-binding site. Mutagenic substitution of residues Tyr256, Pro336, Tyr338 and Lys389 in the clumping factor, which are proposed to contact the terminal residues ^{408}AGDV^{411} of the γ-chain, resulted in proteins with no or markedly reduced affinity for fibrinogen.

Keywords: adhesins/clumping factor A/crystal structure/immunoglobulin fold/*Staphylococcus aureus*

Introduction

Fibrinogen (Fg) is a 340 kDa glycoprotein that is found at a concentration of ~3 mg/ml in blood plasma and plays key roles in hemostasis and coagulation (Herrick *et al*., 1999). Fg is composed of six polypeptide chains, two Aα, two Bβ and two γ-chains, arranged in a symmetrical dimeric structure. The C-terminal residues of the γ-chain represent a biologically important part of Fg that interacts with the platelet integrin $\alpha_{II}\beta_3$ during Fg-dependent platelet adherence and aggregation (Kloczewiak *et al*., 1984). This region of the γ-chain is also targeted by the pathogenic bacterium *Staphylococcus aureus*, resulting in Fg-dependent cell clumping and tissue adherence (Hawiger *et al*., 1982a,b). Clumping factor A (ClfA) was the first Fg γ-chain-binding *S.aureus* adhesin identified, and later the fibronectin-binding proteins A and B (FnbpA and B) of the bacterium were recognized as bi-functional proteins and found to bind the same C-terminal peptide segment in the γ-chain of Fg (Wann *et al*., 2000). Detailed characterization of the binding of these adhesins, which belonged to the family of MSCRAMMs (microbial surface components recognizing adhesive matrix molecules) (Patti and Höök, 1994; Höök and Foster, 2000), to Fg have indicated that the C-terminal residues Ala408-Gly-Asp-Val411 of the γ-chain are critical in these interactions (Strong *et al*., 1982; McDevitt *et al*., 1994, 1997; Wann *et al*., 2000).

ClfA and the Fnbps have structural features that are common to other cell wall-anchored proteins expressed by Gram-positive bacteria, including ClfB, another *S.aureus* Fg-binding MSCRAMM that binds specifically to the α-chain (Figure 1A) (Patti and Höök, 1994; Nì Eidhin *et al*., 1998). These include an N-terminal signal sequence (S) and C-terminal features that are required for sorting the proteins to the cell wall [a proline-rich wall-spanning region (W), the wall-anchoring LPTXG motif, a hydrophobic transmembrane region (M) and a cytoplasmic tail of positively charged amino acid residues (C)]. ClfA and ClfB also contain a Ser-Asp repeat region (R region) in the C-terminal part of the protein, whereas the Fnbps contain C-terminal repeats (D repeats) that bind to fibronectin (Wann *et al*., 2000). The Fg-binding activity of these MSCRAMMs has been localized to the N-terminal A regions that are ~500 amino acid residues long (Figure 1A) (McDevitt *et al*., 1995; Nì Eidhin *et al*., 1998; Wann *et al*., 2000). In the case of ClfA, the Fg-binding site has been further localized to residues 221–559. Furthermore, substitution of Glu526 and Val527 within the minimum Fg-binding truncate of ClfA [$rClfA_{(221–559)}$] with Ala and Ser, respectively, abrogated the Fg-binding activity of this protein (Hartford *et al*., 2001).

Analogous to $\alpha_{II}\beta_3$ (Smith *et al*., 1994), the Fg-binding activity of ClfA is affected by the divalent cations Ca^{2+} and Mn^{2+}. High concentrations of both cations inhibit Fg-dependent bacterial clumping and the binding of rClfA to isolated Fg. A putative cation-binding EF-hand-like motif (residues 310–321) has been proposed within the A region of ClfA (Figure 1A) (O'Connell *et al*., 1998).

In a previous study, we reported the crystallization of recombinant fragments of the ligand-binding A regions of ClfA and ClfB (Deivanayagam *et al*., 1999). These fragments, encompassing residues 221–559 and 199–542

© European Molecular Biology Organization

of rClfA and rClfB, respectively, arose from the N-terminal degradation of the full-length *Escherichia coli*-expressed A regions. Subsequently, it was reported that the N-terminal region (residues 45–220) of native *S.aureus*-expressed ClfB was cleaved by the *S.aureus* metalloprotease aureolysin, generating small peptides that could not be detected by SDS–PAGE (McAleese *et al.*, 2001).

In the present study, we report the crystal structure of the proteolytically stable minimum Fg-binding truncate of ClfA, rClfA$_{(221–559)}$ (Figure 1A). This protein consists of two domains of a new variant of the immunoglobulin



Fig. 1. The Fg-binding MSCRAMMs of *S.aureus*: ClfA, ClfB, FnbpA and FnbpB. (**A**) The four Fg-binding MSCRAMMs of *S.aureus* identified so far have a common structural organization including a signal peptide(s) followed by the N-terminal ligand binding A region in which three subdomains, N1, N2 and N3, can be identified. The boundary between N2 and N3 is indicated by a conserved Tyr residue. At the C-terminus, the cell wall-binding region (W), the membrane-spanning domains (M) and the charged C-terminus (C) are present. ClfA has a unique putative EF-hand in the ligand binding A region and a 'DS' dipeptide repeat R region. ClfB is similar to ClfA and contains an additional proline-rich segment linking the A- and the R-regions. FnbpA and FnbpB contain the unique fibronectin-binding D repeats and B repeats of unknown function. (**B**) Sequence alignment of the N-terminal two-thirds of rClfA$_{(221–559)}$ with corresponding regions of ClfB, FnbpA and FnbpB. Red, blue and black letters represent charged, polar and hydrophobic residues, respectively. Identical residues are shaded and a conserved Tyr residue in the connector between the N2 and N3 domains is boxed. The secondary structural elements are colored in rainbow fashion similar to Figures 2, 4 and 5.



Fig. 2. Domain structure of rClfA$_{(221–559)}$. (**A**) Stereo ribbon diagram of the ClfA crystal structure. In the two independent domains, the β-strands A–G are colored in rainbow fashion. The N- and C-termini and the boundary between the domains indicated by Y369 are also labeled. Each domain has a coordinate axis defined by the relative orientation of the sheets. The long, black axis is the average sheet direction. The silver spheres represent the metal ions. (**B**) Structure-based sequence alignment of the ClfA N2 and N3 domains. The strands A–G are marked with arrows colored as in the ribbon diagrams. Ranges of residues where all Cα superpose within 1.5 Å are boxed. Hydrophobic residues are black, polar are blue and charged are red. Identical residues are highlighted with gray. (**C**) Superposition of the ClfA N2 and N3 domains. Stereo ribbon diagrams of the two domains are overlaid. β-strands A–G are labeled and colored as above. The coil regions of the first domain are dark gray, the coil linking the two domains is light gray and the coils of the second domain are shown in white. The average sheet direction is aligned with the *y*-axis, and the average direction between adjacent strands with the *x*-axis.

(IgG) fold, which we called the DE-variant (DEv) IgG fold. Furthermore, using a combination of molecular modeling and site-directed mutagenesis, we tentatively localize the binding site in $rClfA_{(221–559)}$ for the C-terminal residues (Ala408-Gly-Asp-Val411) of the Fg γ-chain.

Results

Overall structure of $rClfA_{(221–559)}$

The structure of $rClfA_{(221–559)}$ is composed of two compact domains that we have named N2 and N3, respectively, each being dominated by anti-parallel β-strands (Figure 2A). The term N1 was assigned to the protease-sensitive N-terminal segment corresponding to residues 45–220 of the ClfA A region. The new N-terminal N2 domain contains a single-turn α-helix and two 3_{10} helices, while the N3 domain contains three 3_{10} helices. N2 represents the smaller domain, being composed of 140 residues (229–369), whereas the N3 domain encompasses 189 residues (370–559). No electron density was observed for the 20 N-terminal residues, which include 12 residues contributed by the vector His_6 tag sequence and residues 221–228 of the $rClfA_{(221–559)}$ protein. Likewise, no electron density was observed for the two C-terminal residues, which originated from the expression vector. In addition, residues Gly532-Ser-Gly-Ser-Gly-Asp-Gly-Ile539 in the N3 domain did not have interpretable electron densities and were thus modeled into fragments of residual density over several cycles of refinement.

Although metal ions were not added to the buffers and precipitants used in the crystallization protocol, three metal ions (M1, M2 and M3) with octahedral coordination geometry are present in the $rClfA_{(221–559)}$ crystal structure (Figure 2A). The residues of the putative EF-hand-like motif (residues 310–321), which was previously identified within the ClfA primary structure (O'Connell *et al*., 1998), are not involved in coordinating any of these metal ions.



Fig. 3. Structure of metal binding site M1. A representative $2f_o - f_c$ electron density map (rendered from a normalized map at 1.0σ level) displays octahedral coordination of the metal binding site M1, where three main-chain carbonyl oxygen atoms from Asn267, Ala269 and Val323 contribute together with three water molecules (W622, W627 and W719) to the coordination geometry.

Furthermore, the secondary structure of this region is composed of a β-turn followed by a β-strand and does not resemble the classical EF-hand motif (Kretsinger, 1996). The metal ions M1, M2 and M3 are principally coordinated through main-chain carbonyl oxygen atoms, with the exception of M3, which interacts with one side-chain carboxylate (Figure 3). Such metal ion coordination contrasts with that of other metal-binding motifs, where most of the coordination occurs via the side chains, specifically through the carboxylates (Kretsinger, 1996; Springer *et al*., 2000). In macromolecular crystal structures, the coordination number can vary from four to seven for Ca^{2+} and from four to six for Mg^{2+}. The coordination number of six observed for M1, M2 and M3 in the $rClfA_{(221–559)}$ structure suggests that these metal ions might represent Mg^{2+}. However, the average bond length of 2.37 Å observed at these coordination sites is suggestive of Ca^{2+} rather than Mg^{2+}, where the average bond length would be expected to be 2.1 Å. The *B*-factors of these proteins are slightly higher than normal and indicate the possibility of a partial occupancy. Thus, the exact identity of the metal ions (Ca^{2+} or Mg^{2+}) in the $rClfA_{(221–559)}$ structure could not be resolved from the refinement parameters.

The novel DEv-IgG fold

Primary sequence alignment of the N2 and N3 domains revealed 13% amino acid identity and 36% amino acid similarity over their entire lengths (Figure 2B). The secondary structural elements of these domains (boxed residues in Figure 2B) superpose with a root mean square deviation (r.m.s.d.) (on Cα) of 0.97 Å, highlighting the near identity of their structural motifs (Figure 2C). The topology of the N2 and N3 domains resembles that of the jelly roll barrel, yet differs in that the characteristic anti-parallel N- and C-terminal β-strands of the jelly roll fold (Branden and Tooze, 1999) are absent and are replaced by parallel β-strands. In this respect, the topology of the N2 and N3 domains more closely resembles that of the IgG fold (Figure 4A). In fact, we propose that the N2 and N3 structures represent a new variant of this fold (D-variant or DEv-type) that differs from the previously described V-, C-, H- and I-type folds of the immunoglobulin superfamily (Bork *et al*., 1994; Harpaz and Chothia, 1994). In the constant IgG fold (C-type), strands ABED and GFC are arranged at the front and back sides, respectively, of the fold (Figure 4A), whereas in its variants (V-, H- and I-type), additional structural elements are found between strands C and D. The structure of the N2 and N3 domains of $rClfA_{(221–559)}$ follows the topological arrangement of the IgG fold from strands A through D, with the prominent variation occurring between strands D and E, where two additional β-strands (D′ and D″) are observed in each of the two domains in $rClfA_{(221–559)}$ (Figure 4B). Resuming from strand E through G, the topology of N2 and N3 again conforms to the IgG fold. Most of the variable region observed between strands D and E is on one side of the fold (on the right-hand side in Figure 4B), and does not perturb the core region of the IgG fold.

A search for similar structures in the Protein Data Bank (PDB) using the DALI server (Holm and Sander, 1993, 1994; Symersky *et al*., 1997) revealed that the DEv-IgG fold could be assigned to other crystal structures that were



Fig. 4. Topology of the IgG and MSCRAMM domains. Ribbon diagrams of the labeled strands A–G colored in rainbow fashion as in Figure 2. The corresponding topology diagram of the structure is shown to the right. (**A**) IgG-C domain. (**B**) ClfA N2 domain [rClfA$_{(221–559)}$]. (**C**) CNA19 domain (CNA$_{169–318}$). (**D**) Superposition of IgG, rClfA$_{(221–559)}$-N2 and CNA$_{169–318}$.



Fig. 5. Ribbon diagram of crystal structures with the DEv-IgG fold colored in rainbow fashion as in Figures 2 and 4. (**A**) N2 domain of ClfA. (**B**) Receptor-binding domain of α2-macroglobulin (PDB code: 1AYO, *Z*-score: 8.7, r.m.s.d.: 2.8, equiv. resid: 133). (**C**) Calf-2 domain of extracellular segment of the integrin αVβ3 (PDB Code: 1JV2, *Z*-score: 8.4, r.m.s.d.: 12.3, equiv. resid: 149). (**D**) Cohesin domain from the scaffolding protein of *Clostridium thermocellum* (PDB Code: 1AOH, *Z*-score: 7.6, r.m.s.d.: 3.4, equiv. resid: 123). (**E**) The R-domain of diphtheria toxin (PDB Code: 1DDT, *Z*-score: 7.2, r.m.s.d.: 4.2, equiv. resid: 129). (**F**) The cellulosomal scaffolding protein (PDB Code: 1NBC, *Z*-score: 7.0, r.m.s.d.: 3.0, equiv. resid: 109). *Z*-scores, r.m.s.d. values and equiv. resid. are from DALI.

previously referred to as jelly roll barrels. Structures that we propose contain this new variant of the IgG fold include a truncate of the A region of the *S.aureus* collagen-binding MSCRAMM CNA, CBD19 [$CNA_{169–318}$] (Symersky *et al*., 1997). The topology of the $CNA_{(169–318)}$ structure is identical to that of the N2 and N3 domains of $rClfA_{(221–559)}$ in the core regions. However, an additional β-strand (Dα) and a α-helix are found before strands D′ and D″ in $CNA_{(169–318)}$ (Figure 4C and D). In addition, the DEv-IgG fold can be assigned to the receptor-binding domain of α2-macroglobulin (Jenner *et al*., 1998; 1AYO; Figure 5B), the Calf-1 and -2 domains of the extracellular region of the integrin $\alpha_V\beta_3$ (Xiong *et al*., 2001; 1JV2; Figure 5C), the cohesin domain from the scaffolding protein of *Clostridium thermocellum* (Tavares *et al*., 1997; 1AOH; Figure 5D), the 'R' domain of diphtheria toxin (Choe *et al*., 1992; 1DDT; Figure 5E) and the cellulose-binding domain from the cellulosomal scaffolding protein (Tormo *et al*., 1996; 1NBC; Figure 5F).

The N2 and N3 DEv-IgG domains of $rClfA_{(221–559)}$ have a domain orientation resembling other proteins containing tandem IgG motifs with characteristic elbow, twist and swivel angles of 151, 56 and –112°, respectively (Deivanayagam *et al*., 2000). The N2 and N3 domains interact with each other and have a combined buried surface area of 925 $Å^2$. A second crystal form (form II) of $rClfA_{(221–559)}$ was identified during the crystallization trials (see Materials and methods) and conformed to the *P*1 space group (Table I). This unit cell packing has two molecules in the asymmetric unit that superpose on each other with an r.m.s.d. (on Cα) of 0.56 Å and with the form I crystal structure with an r.m.s.d. (on Cα) of 0.53 Å. The near identity of the $rClfA_{(221–559)}$ structures derived from two different crystal forms of this protein makes it unlikely that the crystal packing affected the observed N2 and N3 domain interactions. This indicates that the orientation described for these two domains is fairly rigid.

The A regions of S.aureus Fg-binding MSCRAMMs have a common mosaic structure containing DEv-IgG domains

To explore the structural relationship between the *S.aureus* Fg-binding MSCRAMMs, the primary sequence of the C-terminal two-thirds of the A regions of ClfA (residues

Table I. Crystallographic data for $rClfA_{(221–559)}$

Parameter	Form I	Form II
a (Å)	38.70	67.07
b (Å)	80.54	79.20
c (Å)	113.89	49.84
α (°)	90.00	96.82
β (°)	90.00	104.22
γ (°)	90.00	100.32
Space group	$P2_12_12_1$	$P1$
Resolution (Å)	1.9	2.9
$I/\sigma I$	15.7	6.8
R_{sym}[a] (%)	4.4	9.0
V_m (Å^3 Da^{-1})	2.3	2.4
No. of measured reflections	148 963	61 627
Unique reflections	28 604	23 440
Redundancy	5.2	2.6
Completeness (%)	99.0	97.0
% of reflections > 3σ (last shell)	82.7 (61.2)	77.1 (43.4)
Completeness (%) (last shell)	98.7 (95.2)	97.7 (97.4)
No. of molecules in asymmetric unit	1	2
R-factor	20.61	21.58
R_{free}	25.67	30.97
R.m.s.d. (bonds)	0.005	0.009
R.m.s.d. (angles)	1.37	1.360
Average *B*-factor of protein (Å^2)	25.71	27.95
Average *B*-factor of main chain (Å^2)	25.12	26.84
Average *B*-factor of side chain (Å^2)	26.36	27.95
No. of metal ions	3	0
No. of solvent molecules	375	72

[a]$R_{sym} = \Sigma|Ih - \langle Ih\rangle|/\Sigma Ih$, where $\langle Ih\rangle$ is the average intensity over symmetry equivalents.

221–559), ClfB (residues 212–542), FnbpA (residues 194–544) and FnbpB (170–542) were aligned using MPSA (Blanchet *et al*., 2000). In addition, the secondary structural components of each of these sequences were predicted using PHD (Rost and Sander, 1993). The primary sequence alignments display 24% overall amino acid identity. Furthermore, the predicted secondary structural elements of these sequences align well with the core strands (ABCDD′D″EFG) of the two DEv-IgG folds of $rClfA_{(221–559)}$ (Figure 1B). These observations strongly suggest that the two-domain organization and the DEv-IgG fold of $rClfA_{(221–559)}$ are also found in the corresponding regions of ClfB (residues 212–542), FnbpA (residues 194–544) and FnbpB (residues 170–542) (Figure 1A).

Primary and secondary structural alignment of the N-terminal third of these proteins, corresponding to the proposed N1 domain, revealed very little similarity to the N2 and N3 domains (data not shown). However, this region is also predicted to be composed largely of β-sheet structure and may, in fact, be composed of more then one subdomain. Through biophysical analysis of recombinant forms of ClfB, we recently proposed a model for the structural organization of the Fg-binding A region of this protein (Perkins *et al*., 2001). In this model, the A region is composed of at least three domains, N1, N2 and N3, where N1 represents the protease-sensitive N-terminal domain that is degraded by the *S.aureus* protease aureolysin (Figure 1A) (McAleese *et al*., 2001). Now, we extend this model further and propose that the full-length A regions of all four *S.aureus* Fg-binding MSCRAMMs possess a similar multi-domain architecture that is composed of at least three domains: N1, N2 and N3 (Figure 1A).

Docking of the C-terminal residues of the Fg γ-chain

The C-terminal region of the Fg γ-chain (residues 398–411) is perceived to be a flexible structure that can adopt multiple conformations, enabling it to bind with specificity to different receptors, including the platelet integrin $\alpha_{II}\beta_3$, and the MSCRAMMs ClfA, FnbpA and FnbpB (Hawiger *et al*., 1982a,b; Mayo *et al*., 1990). Consistent with this flexibility, the electron density of this region has been reportedly poor in the crystal structures of intact Fg and the appropriate fragments thereof (Pratt *et al*., 1997; Spraggon *et al*., 1997). In an attempt to elucidate the crystal structure of the C-terminal residues of the γ-chain (residues 398–411), a novel carrier protein-driven crystallization method involving both hen egg lysozyme (HEL) and glutathione *S*-transferase (GST) was used (Donahue *et al*., 1994; Ware *et al*., 1999). While the crystal structures of the γ-chain residues obtained in each case were very similar, displaying a general Z shape, two sites of large structural difference were observed, His401-Leu402 and Lys406-Gln407, which may represent different conformational states of the C-terminal γ-chain residues. The main-chain atoms of the terminal residues Ala408-Gly-Asp-Val411 were nearly identical in these structures and superposed with an average r.m.s.d. (on Cα) of 0.94 Å. However, the side chains appeared to adopt varying conformations, indicating flexibility of the termini.

The γ-chain peptide crystal structures that were determined from the HEL and GST studies (1LSG and 1DUG, respectively) were used to model the $rClfA_{(221–559)}$–γ-chain peptide complex. A brute force docking procedure (Materials and methods; Jiang and Kim, 1991) implemented in SoftDock (M.Carson, unpublished data) was used to dock the 15 residue γ-chain peptide onto $rClfA_{(221–559)}$. The top 20 solutions were examined and were further scored on the basis of the essential interaction of the γ-chain Ala408-Gly-Asp-Val411 residues with $rClfA_{(221–559)}$ (McDevitt *et al*., 1997; O'Connell *et al*., 1998). For seven of the top 20 solutions, the C-terminal γ-chain Ala408-Gly-Asp-Val411 residues were found to be extensively in contact with $rClfA_{(221–559)}$ residues. In all of these solutions, the Fg γ-chain peptide docked into a hydrophobic pocket formed at the interface between the N2 and N3 domains (Figure 6A). This hydrophobic pocket contains the Val527 residue that was previously shown to be important for the interaction of $rClfA_{(221–559)}$ with the γ-chain peptide (Figure 6B) (Hartford *et al*., 2001). Moreover, this Val residue is also present in FnbpB (Val464) and appears as a conserved substitution in FnbpA (Leu498). Both of these MSCRAMMs are known to interact with the C-terminal residues of the γ-chain (Figure 1B) (Wann *et al*., 2000). In our current model, the Val527 residue in the hydrophobic pocket of $rClfA_{(221–559)}$ interacts with the terminal Val411 residue of the γ-chain peptide. It is possible that replacement of Val527 with a Ser residue displaced the charge balance in this pocket, disrupting the hydrophobic interaction with Val411 in the γ-chain. Other residues of $rClfA_{(221–559)}$ that appear to interact with the Ala408-Gly-Asp-Val411 residues of the γ-chain in this model are Tyr256, Pro336 and Tyr338 in the N2 domain, and Ile387 and Lys389 in the N3 domain. Besides



Fig. 6. (**A**) Stereo surface plot showing seven solutions of the Fg γ-chain peptide docked into a hydrophobic pocket between N2 and N3 domains. The hydrophobic, polar, positive and negative residues are shown in white, magenta, blue and red, respectively. Cyan and gold represent hydrogen bond donors and acceptors, respectively. (**B**) Stereo ribbon diagram showing the interactions of residues ^{408}AGDV^{411} (blue) of the γ-chain of Fg with residues from both the N2 (dark gray) and N3 (white) domains of rClfA$_{(221–559)}$. The ribbon of the glycine-rich region ^{532}GSGSGDGI^{539} is colored in orange.

these interactions, several residues in the flexible loop region Gly532-Ser-Gly-Ser-Gly-Asp-Gly-Ile539 within rClfA$_{(221–559)}$ (colored orange in Figure 6B) also interact with the γ-chain peptide and form the backdrop for this suggestive binding site.

Mutational analysis of rClfA$_{(221–559)}$

To test our docking model, we investigated the role of Ala254, Tyr256, Pro336, Tyr338, Ile387 and Lys389 residues that are present at the mouth of the hydrophobic pocket of rClfA$_{(221–559)}$. These residues were targeted by site-directed mutagenesis, being substituted by an Ala or Ser residue. The far-UV circular dichroism (CD) spectra of the mutant proteins were not detectably different from that of the wild-type rClfA$_{(221–559)}$ protein (data not shown), suggesting that the substitutions did not dramatically alter the conformation of the protein. The interaction of the mutant rClfA$_{(221–559)}$ proteins with immobilized intact Fg was analyzed in a direct ELISA-type binding assay (data not shown) and also in an inhibition ELISA-type assay in which the ability of the mutant proteins to inhibit the binding of soluble biotin-labeled wild-type rClfA$_{(221–551)}$ to immobilized Fg was determined (Figure 7). The Y_{338}A mutant protein failed to bind to immobilized Fg in either assay, whereas the Y_{256}A, K_{389}A and P_{336}S mutant proteins exhibited markedly reduced apparent affinity for immobilized Fg. In addition, the A_{254}S and I_{387}S mutant proteins had somewhat reduced apparent affinities. Fluorescence polarization was used to further characterize the binding of the wild-type and mutant ClfA$_{(221–551)}$



Mutations	Binding Kd (μM)
◊ Y338A	ND
□ Y256A	59.7+/-7.7
● w. t.	8.4+/-1.6
Δ P336S	64.2+/- 55.6
+ P336A	42.5+/-19.0
× K389A	60.0+/-45.3
▲ A254S	28.9+/- 6.7
▼ I387S	10.9+/- 2.2

Fig. 7. (**A**) The relative affinities of $rClfA_{221–559}$w.t. (closed circles), $rClfA_{221–559}Y_{256}\rightarrow A$ (open squares) and $rClfA_{221–559}Y_{338}\rightarrow A$ (open diamonds) for Fg were examined in an inhibition ELISA-type assay (Smith *et al*., 1993). Biotin-labeled $rClfA_{221–559}$ was incubated with the indicated increasing concentration of unlabeled ClfA proteins in Fg-coated microtiter wells. The amount of labeled ClfA protein bound to the immobilized Fg was then quantitated. The K_d of each protein was calculated by determining the affinity of the proteins for a fluorescein-labeled 17-amino-acid-long synthetic peptide representing the C-terminus of the Fg γ-chain using fluorescence polarization. (**B**) The relative affinities of $rClfA_{221–559}A_{254}\rightarrow S$ (upright closed triangles), $rClfA_{221–559}I_{387}\rightarrow S$ (inverted closed triangles), $rClfA_{221–559}$ $K_{389}\rightarrow A$ (×), $rClfA_{221–559}P_{336}\rightarrow A$ (+), $rClfA_{221–559}P_{336}\rightarrow S$ (open upright triangles) for Fg were examined in the same way as above. K_d was also calculated as indicated.

proteins to a fluorescein-labeled 17-amino-acid-long synthetic peptide corresponding to the C-terminus of the Fg γ-chain. The corresponding K_D values were calculated from these assays (Figure 7). The $Y_{338}A$ mutant protein failed to bind to the γ-chain peptide in this assay, whereas the $Y_{256}A$, $K_{389}A$ and $P_{336}S$ mutant proteins exhibited markedly reduced affinity for the labeled peptide (K_D = 49–65 μM) compared with the wild-type $rClfA_{(221–559)}$ protein (K_D = 8 μM). The K_D values determined for the binding of the $A_{254}S$ and $I_{387}S$ protein to γ-chain peptide were 29 and 11 μM, respectively. Taken together, these results support the docking experiments and tentatively identify the hydrophobic pocket between the N2 and N3 domains as the binding site in ClfA for the C-terminal residues of the Fg γ-chain.

Discussion

Nearly a century ago, Much (1908) first reported the clumping of *S.aureus* in the presence of blood plasma, which was later shown to be Fg dependent, indicating the mediation of Fg-binding surface proteins in the clumping phenomenon. The crystal structure of $rClfA_{(221–559)}$, which represents the minimum truncate of ClfA with Fg-binding activity, has now been determined. Recombinant $rClfA_{(221–559)}$ structure is composed of two discrete subdomains that have a very similar fold. This fold, which we have called DEv-IgG, represents a novel variation of the IgG fold. The topology of the DEv-IgG fold is very similar to that of the C-type IgG fold, but displays variation between the D and E strands on one side of the motif (right side in Figure 4B). From primary structure alignment and secondary structure prediction, it appears likely that the C-terminal two-thirds of the Fg-binding A regions of ClfB, FnbpA and FnbpB also contain two subdomains that display the DEv-IgG fold. In addition, we discovered that the minimum ligand-binding region of the collagen-binding MSCRAMM, $CNA_{(151–318)}$, which corresponds to the central part of the A region of this protein, also displays this fold (Symersky *et al*., 1997). Interestingly, we previously reported that the B repeats of CNA display the Inv-IgG fold, yet another variant of the immunoglobulin superfamily (Deivanayagam *et al*., 2000). Based on the crystal structure of $rClfA_{(221–559)}$, previous biophysical analysis of rClfB, and primary and secondary structure alignments of all four *S.aureus* Fg-binding MSCRAMMs, we propose that the A regions of these proteins contain at least three domains: N1, N2 and N3. N1 represents the N-terminal region, which, at least in the case of ClfA and ClfB, is known to be protease sensitive (Deivanayagam *et al*., 1999; McAleese *et al*., 2001). Thus, we propose that the A regions of these MSCRAMMs are mosaic proteins containing several immunoglobulin-like domains. The manifestation of MSCRAMMs through modules of IgG fold with varying functional characteristics (binding to different targets) suggests the evolution of these motifs from a common template. It is of interest to note that cell surface adhesins of Gram-negative bacteria, including invasin (Hamburger *et al*., 1999), FimC (Pellecchia *et al*., 1998) and FimH (Choudhury *et al*., 1999), contain domains of the traditional immunoglobulin superfamily. Furthermore, many eukaryotic cell adhesion molecules, such as ICAMs, VCAMs and MAdCAM, also contain these domains (Wang and Springer, 1998) and the recently solved $\alpha_V\beta_3$ integrin structure contain domains of the newly identified DEv-IgG fold. It is tantalizing to speculate that a structural organization encompassing the now extended superfamily of immunoglobulin folds is critical for the activity of these adhesion receptors.

Table II. Heavy atom derivative statistics for $rClfA_{(221–559)}$

Heavy atom compound	Resolution (Å)	R_{sym}[a] (%)	Unique reflections	Solve		Phases	
				$R_{centric}$	R.M.S. (FH)/ R.M.S.(E)	R_{cullis}[b]	Phasing power[c]
$(CH_3)_3PbOOCCH_3$	2.45	6.2	13 162	0.57	1.35	0.567	1.98
K_2PtCl_4	3.2	16.3	7177	0.64	1.22	0.657	1.15
PCMBS	3.0	7.2	7450	0.56	1.42	0.628	1.45

[a]$R_{sym} = \Sigma|Ih - \langle Ih\rangle|/\Sigma Ih$, where $\langle Ih\rangle$ is the average intensity over symmetry equivalents.
[b]$R_{cullis} = \Sigma||F_{PH} \pm F_P| - F_{Hcalc}|/\Sigma|F_{PH} - F_P|$
[c]Phasing power $= \Sigma|F_H|/\Sigma||F_{PH}obs| - |F_{PH}calc||$

In the crystal structure of $rClfA_{(221–559)}$, it was revealed that the putative EF-hand-like motif was composed of a β-turn followed by a β-strand, a structure that does not resemble a classical EF-hand. Therefore, this observation does not support the previously suggested models for ClfA–metal ion interactions (O'Connell *et al*., 1998). However, a role for the three metal ion-binding sites, identified in the crystal structure of $rClfA_{(221–559)}$, in ClfA–ligand interactions can not be ruled out at this point. Studies are in progress to further characterize these metal ions, their binding sites, and role in ClfA structure and function.

Brute force docking of the terminal residues (398–411) of the γ-chain into the $rClfA_{(221–559)}$ structure produced seven solutions that docked into the hydrophobic pocket formed between the N2 and N3 domains. In an earlier study, the replacement of Val527 (which we now have located inside this pocket) with Ser resulted in a loss of Fg-binding activity (Hartford *et al*., 2001). From the present model, it is apparent that such a substitution would disrupt the charge balance in the pocket and would thus be deleterious to the hydrophobic interactions with the terminal Val411 of the γ-chain. Besides the hydrophobic interactions described above, the Ala408-Asp-Gly-Val411 of the γ-chain in our proposed model also have charge-to-charge interactions with Tyr256 (N2) and Tyr338, and Lys389 (N3) present at the mouth of the pocket. Substitution of these residues with Ala resulted in mutant proteins with no detectable or a markedly reduced apparent affinity for Fg. Furthermore, sequence analyses of the N3 domain of ClfA from a number of *S.aureus* strains (Newman, 8324-5, COL, MRSA252, MSSA476, N315, Mu50, RN4256, Cowan I, MN8, Yeh, McNamara, P1 and BB) revealed that the amino acids in the hydrophobic pocket that we propose are involved in binding to the γ-chain of Fg are all conserved (data not shown). We have also observed that the independently expressed recombinant N2 and N3 domains fail to bind to Fg (data not shown), providing additional support for the hypothesis that both domains contribute to the formation of the Fg-binding site. The flexible Gly-rich sequence (Gly532-Ser-Gly-Ser-Gly-Asp-Gly-Ile539) perhaps provides the cushion for the flexible γ-chain peptide to permeate into the hydrophobic pocket (Figure 6B), and this region could potentially acquire a stable structure in the ClfA–γ-chain complex.

The *S.aureus* MSCRAMMs ClfA (McDevitt *et al*., 1997; O'Connell *et al*., 1998), FnbpA and FnbpB (Wann *et al*., 2000) bind to the C-terminal residues of the γ-chain, a region that is also involved in platelet aggregation (Farrell *et al*., 1992) and fibrin monomer cross-linking during the formation of a fibrin clot (Chen and Doolittle, 1969). Similarly, SdrG, a Fg-binding MSCRAMM from *Staphylococcus epidermidis*, binds to an N-terminal segment of the Fg β-chain that overlaps with the thrombin cleavage site (Davis *et al*., 2001). The fact that these staphylococcal MSCRAMMs bind to the terminal amino acids of various Fg chains that are involved in physiological processes is an intriguing observation. Whether staphylococci target these flexible regions of Fg to inhibit its physiological function, or simply because these regions are easily accessible, is a question that remains to be answered.

Materials and methods

Purification of recombinant proteins

For crystallization, the rClfA(221–599) protein, which is equivalent to the proteolytic product ClfA37 (Deivanayagam *et al*.,1999), was expressed in *E.coli* and purified by immobilized metal chelate affinity chromatography, followed by anion-exchange and gel-filtration chromatography, as described previously (O'Connell *et al*., 1998; Deivanayagam *et al*., 1999). The purity and molecular mass of the $rClfA_{(221–559)}$ protein were analyzed by SDS–PAGE and MALDI mass spectroscopy, respectively. For the Fg-binding assays, the rClfA proteins were expressed and purified as above, except that the final gel-filtration purification step was not performed.

Crystallization and data collection

Form I. A droplet made from 2 μl of $rClfA_{(221–559)}$ at 20 mg/ml and 2 μl of 1.2 M sodium citrate, 100 mM succinic acid at pH 5.6 was equilibrated against a reservoir containing 1 ml of 1.2 M sodium citrate, 100 mM succinic acid at pH 5.6. After 1 week, the crystals grew to 0.4 × 0.3 × 0.15 mm. These crystals were 'flash' frozen without any addition of cryo-protectants and were subjected to X-rays generated on the X-9B beamline at the Synchrotron light source in the Brookhaven National Laboratories (BNL). Diffraction data to 1.9 Å resolution were collected on a MAR CCD detector at a distance of 170 mm with a 0.5° oscillation sweeping the reciprocal lattice with 262 frames (131°) at 0.91676 Å wavelength (λ). Data were integrated and scaled using DENZO and SCALEPACK (Otwinowski, 1993), and the data statistics are reported in Table II.

Form II. High concentrations of Ca^{2+} or Mn^{2+} interfere with the $rClfA_{(221–559)}$–γ-chain interactions and hence $rClfA_{(221–559)}$ was dialyzed into a solution containing 20 mM Tris pH 8.0, 100 mM NaCl and 5 mM EDTA, as opposed to 1 mM EDTA reported in the form I crystallization condition. The 17 residue synthetic peptide ^{395}GEGQQHHLGGAK-QAGDV^{411} imitating the C-terminal residues of the γ-chain of Fg was mixed at 1:20 molar ratio and incubated at 4°C overnight with purified $rClfA_{(221–559)}$ (0.1 mg/ml) with occasional gentle stirring. The above solution was then concentrated under 40 p.s.i. argon gas pressure using the Amicon micro-ultrafiltration system with a YM10 membrane. The

concentrated protein–peptide mixture was used to set up hanging drop crystallization trials. Large diamond-shaped single crystals measuring 0.3 × 0.3 × 0.1 mm were grown from a droplet made of 3 μl of the protein–peptide mixture (14 mg/ml) and 3 μl of the well solution containing 200 mM ammonium acetate, 100 mM sodium citrate dihydrate pH 5.6 and 26% (w/v) PEG4000. Crystals were flash frozen in the presence of 15% glycerol and diffraction data were collected at BNL (X-9B) on a MAR CCD detector at a distance of 220 mm with a 1.0° oscillation sweeping the reciprocal lattice with 276 frames (276°) at 0.98 Å wavelength (λ). Data were integrated and scaled using DENZO and SCALEPACK and the data statistics are reported in Table I. The form II crystals diffracted poorly (2.9 Å resolution) compared with the form I crystals (1.9 Å resolution).

Structure determination and refinements

Form I. The structure was solved by the MIR (multiple isomorphous replacement) method. Three derivatives, trimethyl lead acetate (TMLA), potassium platinum tetrachloride (PPT) and *p*-chloromercuri-benzene-sulfonic acid (PCMPS), were identified by difference Patterson analysis using the program XTALVIEW (McRee, 1993). The details of the heavy atom derivative statistics are presented in Table II. The PPT and PCMPS derivatives had one site each, whereas TMLA had two. Refinement of heavy atom derivatives and subsequent phase calculations were performed using the program PHASES (Furey and Swaminathan, 1997) and SOLVE (Terwilliger and Berendzen, 1999). An initial 3.5 Å electron density map clearly defined the solvent and revealed well-connected main-chain densities. The initial Cα trace was made using the baton mode in O (Jones *et al*., 1991). Side chains were incorporated into the model and further refinements were carried out with ARP/WARP (Perrakis *et al*., 1999) and CNS-Solve-1.0 (Adams *et al*., 1997). All reflections (⩾2σ) from 100 to 1.9 Å were used in refinement, with 10% partitioned in a test set for monitoring the refinement process (Brünger, 1992). The initial R-factor/R_{free} of the fully built model with side chains was 33.9%/41.0%. The molecular model building was performed with the help of the graphics program O, in conjunction with Oops (Kleywegt and Jones, 1997). Solvent molecules were added based on geometry and electron density, and model convergence was achieved after several cycles of model building and refinement. Maximum likelihood refinement and bulk solvent correction were performed with CNS-Solve in the last few cycles, resulting in 375 solvent molecules and three metal ions in the asymmetric unit with the final R-factor/R_{free} being 20.6%/25.7%. The average B-factor for the protein is 25.71 $Å^2$. The model has 99.4% of the residues in the allowed regions of the Ramachandran plot, two residues in the generously allowed regions and one of these residues (Asp330) appears in a loop region where the electron density is not clearly defined.

Form II. The crystal structure of form II was solved by the molecular replacement method, where the crystal structure of form I was used as the initial model. Self-rotation function calculated using 15–4 Å resolution diffraction data revealed one strong peak (60% of the origin peak) at ω = 210° and φ = 162 ° in the κ = 180° section, indicating the presence of a non-crystallographic two-fold. A good rotation solution was obtained using the program AMoRe (Navaza, 1994) and positional searches initiated using the best rotations produced two strong translational peaks. After fixing the orientation and position of one molecule, the rotation and translation values for the second molecule were obtained. Each model was subjected to rigid body refinement using AMoRe and expressed an R-factor of 35.4% and correlation coefficient of 0.54. These two molecules were further refined in CNS using the simulated annealing protocol where their R-factor/R_{free} fell from 42.8%/42.3% to 26.9%/34.0%. Several cycles of model building were carried out using program O in conjunction with Oops, and the last few cycles were subjected to maximum likelihood refinement and bulk solvent correction incorporated in CNS-Solve-1.0. The addition of 5 mM EDTA chelated the metal ions in this structure, and with 90 solvent molecules in the asymmetric unit the model had a final R-factor/R_{free} of 21.58%/30.97% (resolution 100–3.2 Å). This model had an average B-factor of 27.95 $Å^2$, which is comparable to that of form I, and has all the residues within the allowed regions of the Ramachandran plot. On the difference Fourier maps, residual density was observed in a region of contact between the two asymmetrically related molecules that could accommodate three polyalanine residues. However, after several cycles of model building and refinements, the improved phases did not extend the residual density to account for the 17 residue peptide.

Orientation and superposition of domains

The orientation of all the figures and superposition presented in this paper were performed using the common-coordinate system, as described previously (Deivanayagam *et al*., 2000). All the figures in this paper were made using the program RIBBONS (Carson, 1997).

Buried surface area

The analytical molecular surface area was calculated using the MSP program (Connolly, 1993). The coordinates of the two domains, D_1 and D_2, were combined to form D_1D_2 and the surface area determined for each set. The combined buried surface was approximated with the areas: $D_1 + D_2 - D_1D_2$.

Docking

The docking proceedure holds a target molecule stationary, while a full six degrees of freedom search is performed with the probe molecule. For each discrete rotational orientation (typically ~10 000), a molecular dot surface is calculated and classified per atom type. Each molecule is partitioned into cubes classified as solvent, surface or internal, and then compared cube by cube for each possible translation. The scoring function rewards geometric and chemical complementarity between two surfaces, while penalizing internal volume overlap. The geometric complementarity requires the surface normals to be oriented toward each other, within an angular tolerance. The chemical complementarity is based on the atomic classification as shown in Figure 6A. A simple ±1 sum is accumulated pairwise over the surface dots inside each cube; for example, a positive charge interacting with hydrophobic is –1; a positive charge interacting with a hydrogen-bond acceptor is +1. Details are given in Jiang and Kim (1991).

Site-directed mutagenesis

A two-step, PCR-based, strand overlap extension (SOE) site-directed mutagenesis (Ho *et al*., 1989) procedure was used to specifically substitute the targeted residues in $rClfA_{(221–559)}$. The final PCR products generated were gel purified, digested with *Bam*HI and *Hin*dIII, and ligated into the expression vector pQE30, which had been digested with the same enzymes. The DNA sequence of each of the mutations was verified by automated nucleotide sequencing at the University of Texas, Houston, core facility.

CD spectroscopy

All the protein samples were dialyzed into 1 mM Tris–HCl pH 7.4. Far-UV CD data were collected and the secondary structure composition was estimated as described previously (Hartford *et al*., 2001).

Fg-binding assays

The binding of the rClfA proteins to immobilized intact Fg (Enzyme Research Laboratories) was analyzed in an inhibition ELISA-like assay as described previously (Smith *et al*., 1994). The binding of the rClfA proteins to the fluorescein-labeled C-terminal γ-chain peptide was quantitated by fluorescence polarization, and this method, together with peptide synthesis and labeling procedures, have been described previously (O'Connell *et al*., 1998).

PDB accession code

Coordinates of the $rClfA_{(221–559)}$ structure have been deposited in the Protein Data Bank (accession code IN67).

Acknowledgements

We would like to thank Sita Danthuluri, Shital Patel and Karthe Ponnuraj for their invaluable technical help in setting up crystallization, and Krishna Murthy and Dwight Moore for useful suggestions. This study was supported in part by NIH grant 1AI20624.

References

Adams,P.D., Pannu,N.S., Read,R.J. and Brünger,A.T. (1997) Cross-validated maximum likelihood enhances crystallographic simulated annealing refinement *Proc. Natl Acad. Sci. USA*, **94**, 5018–5023.

Blanchet,C., Combet,C., Geourjon,C. and Deleage,G. (2000) MPSA: integrated system for multiple protein sequence analysis with client/server capabilities. *Bioinformatics*, **16**, 286–287.

Bork,P., Holm,L. and Sander,C. (1994) The immunoglobulin superfamily domains in cell adhesion molecules and surface

receptors belong to a new structural set, which is close to that containing the variable domains. *J. Mol. Biol.*, **242**, 309–320.

Branden,C. and Tooze,J. (1999) *Introduction to Protein Structure*, 2nd edn. Garland Publishing, New York, NY.

Brünger,A.T. (1992) Free *R* value: a novel statistical quantity for assessing the accuracy of crystal structures. *Nature*, **355**, 472–475.

Carson,M. (1997) RIBBONS. *Methods Enzymol.*, **277**, 493–505.

Chen,R. and Doolittle,R.F. (1969) Synthetic peptide probes and the location of fibrin polymerization sites. *Protides Biol. Fluids*, **28**, 311–316.

Choe,S., Bennet,M.J., Fujii,G., Curmi,P.M.G., Kantardjieff,K.A., Coller,R.J. and Eisenberg,D. (1992) The crystal structure of diphtheria toxin. *Nature*, **357**, 216–222.

Choudhury,D., Thompson,A., Stojanoff,V., Langermann,S., Pinker,J., Hultgren,S.J. and Knight,S.D. (1999) X-ray structure of the FimC–FimH chaperone–adhesin complex from uropathogenic *Escherichia coli*. *Science*, **285**, 1061–1066.

Connolly,M.L. (1993) The molecular surface package. *J. Mol. Graph.*, **11**, 139–141.

Davis,S.L., Gurusiddappa,S., McCrea,K.W., Perkins,S. and Höök,M. (2001) SdrG, a fibrinogen-binding bacterial adhesin of the MSCRAMM subfamily of the *Staphylococcus epidermis*, targets the thrombin cleavage site in the β chain. *J. Biol. Chem.*, **276**, 27799–27805.

Deivanayagam,C.C., Perkins,S., Danthuluri,S., Owens,R.T., Bice,T., Nanavathy,T., Foster,T.J., Höök,M. and Narayana,S.V.L. (1999) Crystallization of ClfA and ClfB fragments: the fibrinogen-binding surface proteins of *Staphylococcus aureus*. *Acta Crystallogr. D*, **55**, 554–556.

Deivanayagam,C.C., Rich,R.L., Carson,M., Owens,R.T., Danthuluri,S., Bice,T., Höök,M. and Narayana,S.V.L. (2000) Novel fold and assembly of the repetitive B region of the *Staphylococcus aureus* collagen-binding surface protein. *Structure*, **8**, 67–78.

Donahue,J.P., Patel,H., Anderson,W.F. and Hawiger,J. (1994) Three-dimensional structure of the platelet integrin recognition segment of the fibrinogen γ chain obtained by carrier driven protein crystallization. *Biochemistry*, **91**, 12178–12182.

Farrell,D.H., Thiagarajan,P., Chung,D.W. and Davie,E.W. (1992) Role of fibrinogen α and γ chain sites in platelet aggregation. *Proc. Natl Acad. Sci. USA*, **89**, 10729–10732.

Furey,W. and Swaminathan,W. (1997) PHASES-95: a program package for processing and analyzing diffraction data from macromolecules. *Methods Enzymol.*, **277**, 590–620.

Hamburger,Z.A., Brown,M.S., Isberg,R.R. and Bjorkman,P.J. (1999) Crystal structure of invasin: a bacterial integrin binding protein. *Science*, **286**, 291–295.

Harpaz,Y. and Chothia,C. (1994) The immunoglobulin fold: structural classification, sequence patters and common core. *J. Mol. Biol.*, **238**, 528–539.

Hartford,O.M., Wann,E.R., Höök,M. and Foster,T.J. (2001) Identification of residues in the *Staphylococcus aureus* fibrinogen binding MSCRAMM clumping factor A (ClfA) that are important for ligand-binding. *J. Biol. Chem.*, **276**, 2466–2473.

Hawiger,J.S., Timmons,S., Strong,D.D., Cottrell,B.A., Riley,M. and Doolittle,R.F. (1982a) Identification of a region of human fibrinogen interacting with staphylococcal clumping factor. *Biochemistry*, **21**, 1407–1413.

Hawiger,J., Timmons,S., Kloczewiak,M., Strong,D.D. and Doolittle,R.F. (1982b) γ and α chains of human fibrinogen interacting with staphylococcal clumping factor. *Proc. Natl Acad. Sci. USA*, **79**, 2068–2071.

Herrick,S., Blanc-Brude,O., Gray,A. and Laurent,G. (1999) Fibrinogen. *Int. J. Biochem. Cell Biol.*, **31**, 741–746.

Ho,S.N., Hunt,M.D., Hornton,R.M., Pullen,J.K. and Pease L.R. (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. *Gene*, **77**, 51–59.

Holm,L. and Sander,C. (1993) Protein structure comparison by distant alignment matrices. *J. Mol. Biol.*, **233**, 123–128.

Holm,L. and Sander,C. (1994) Searching protein structure database has come of age. *Proteins*, **19**, 165–173.

Höök,M. and Foster,T.J. (2000) Staphylococcal surface proteins. In Fischetti *et al*. (eds), *Gram Positive Pathogens*, Vol. 40. American Society for Microbiology, Washington, DC, pp. 386–392.

Jenner,L., Husted,L., Thirup,S., Sottrup-Jensen,L. and Nyborg,J. (1998) Crystal structure of the receptor-binding domain of α2-macroglobulin. *Structure*, **6**, 595–604.

Jiang,F. and Kim,S.H. (1991) Soft docking: matching of molecular surface cubes. *J. Mol. Biol.*, **219**, 79–102.

Jones,T.A., Zou,J.Y., Cowan,S.W. and Kjeldgaard,M. (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. *Acta Crystallogr. D*, **47**, 110–119.

Kleywegt,G.J. and Jones,T.A. (1997) Model rebuilding and refinement practice *Methods Enzymol.*, **276**, 208–330.

Kloczewiak,M., Timmons,S., Lukas,T.J. and Hawiger,J. (1984) Platelet receptor recognition site on human fibrinogen. Synthesis and structure–function relationship of peptides corresponding to the carboxy-terminal segment of the γ chain. *Biochemistry*, **23**, 1767–1774.

Kretsinger,R.H. (1996) EF hands reach out. *Nat. Struct. Biol.*, **3**, 12–15.

Mayo,K.H., Bruke,C., Lindon,J.N. and Kloczewiak,M. (1990) 1-H NMR sequential assignments and secondary structure analysis of human fibrinogen γ chain C-terminal residues 385–411. *Biochemistry*, **29**, 3277–3286.

McAleese,M.F., Walsh,E.J. Sieprawska,M. Potempa,J. and Foster,T.J. (2001) Loss of clumping factor B fibrinogen binding activity by *Staphylococcus aureus* involves cessation of transcription, shedding and cleavage by metalloprotease *J. Biol. Chem.*, **276**, 29969–29987.

McDevitt,D., Francois,P., Vaudaux,P. and Foster,T.J. (1994) Molecular characterization of the clumping factor (fibrinogen receptor) of *Staphylococcus aureus*. *Mol. Microbiol.*, **11**, 237–248.

McDevitt,D., Francois,P., Vaudaux,P. and Foster,T.J. (1995) Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of *Staphylococcus aureus*. *Mol. Microbiol.*, **16**, 895–907.

McDevitt,D., Nanavathy,T., House-Pompeo,K., Bell,E., Turner,N., McIntire,L., Foster,T.J. and Höök,M. (1997) Characterization of the interaction between the *Staphylococcus aureus* clumping factor (ClfA) and fibrinogen. *Eur. J. Biochem.*, **247**, 416–424.

McRee,D.E. (1993) *Practical Protein Crystallography*. Academic Press, San Diego, CA.

Much,H. (1908) Uber eine vorstufe des fibrinfer mentes in kulturen von *Staphylokokkus aureus*. *Biochem Z.*, **14**, 143–144.

Navaza,J. (1994) AMoRe: an automated package for molecular replacement. *Acta Crystallogr. A*, **50**, 157–163.

Nì Eidhin,D., Perkins,S., Francois,P., Vaudaux,P., Höök,M. and Foster,T.J. (1998) Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of *Staphylococcus aureus*. *Mol. Microbiol.*, **30**, 245–257.

O'Connell,D.P., Nanavathy,T., McDevitt,D., Gurusiddappa,S., Höök,M. and Foster,T.J. (1998) The fibrinogen-binding MSCRAMM (clumping factor) of *Staphylococcus aureus* has a Ca^{2+}-dependent inhibitory site. *J. Biol. Chem.*, **273**, 6821–6829.

Otwinowski,Z. (1993) *DENZO, a Film Processing Program for Macromolecular Crystallography*. Yale University, New Haven, CT.

Patti,J. M and Höök,M. (1994) Microbial adhesins recognizing extracellular matrix macromolecules *Curr. Opin. Cell Biol.*, **6**, 752–758.

Pellecchia,M., Güntert,P., Glockshuber,R. and Wüthrich,K. (1998) NMR solution of the periplasmic chaperone FimC. *Nat. Struct. Biol.*, **5**, 885–890.

Perkins,S., Walsh,E.J., Deivanayagam C.C.S., Narayana,S.V.L., Foster,T.J. and Höök,M. (2001) Structural organization of the fibrinogen-binding region of the clumping factor B MSCRAMM of *Staphylococcus aureus*. *J. Biol. Chem.*, **276**, 44721–44728.

Perrakis,A., Morris,R.J. and Lamzin,V.S. (1999) Automated protein model building combined with iterative structure refinement. *Nat. Struct. Biol.*, **6**, 458–463.

Pratt,K.P., Côtè,H.C.F., Chung,D.W., Stenkamp,R.E. and Davie,E.W. (1997) The primary fibrin polymerization pocket: three-dimensional structure of a 30 kDa C-terminal γ chain fragment complexed with the peptide Gly-Pro-Arg-Pro. *Proc. Natl Acad. Sci. USA*, **94**, 7176–7181.

Rost,B. and Sander,C. (1993) Prediction of protein secondary structure at better than 70% accuracy. *J. Mol. Biol.*, **232**, 584–599.

Smith,J.W., Piotrowicz,R.S. and Mathis,D. (1994) A mechanism for divalent cation regulation of β3-integrins *J. Biol. Chem.*, **269**, 960–967.

Spraggon,G., Everse, E and Doolittle,R.F. (1997) Crystal structures of fragment D from human fibrinogen and its cross linked counterpart from fibrin. *Nature*, **389**, 455–462.

Springer,T.A., Jing,H. and Takagi,J. (2000) A novel Ca^{2+} binding β hairpin loop better resembles integrin sequence motifs than the EF hand. *Cell*, **102**, 272–277.

Strong,D.D., Laudano,A.P., Hawiger,J. and Doolittle,R.F. (1982) Isolation, characterization and synthesis of peptides from human fibrinogen that block the staphylococcal clumping reaction and construction of a synthetic clumping particle. *Biochemistry*, **21**, 1414–1420.

Symersky,J. *et al*. (1997) Structure of the collagen-binding domain from a *Staphylococcus aureus* adhesin. *Nat. Struct. Biol.*, **4**, 833–838.

Tavares,G.A., Beguin,P. and Alzari,P.M. (1997) The crystal structure of type I cohesin domain at 1.7 Å resolution. *J. Mol. Biol.*, **273**, 701–713.

Terwilliger,T.C. and Berendzen,J. (1999) Automated structure solution for MIR and MAD. *Acta Crystallogr. D*, **55**, 849–861.

Tormo,J., Lamed,R., Chirino,A.J., Morag,E., Bayer,E.A., Shoham, Y and Steitz,T.A. (1996) Crystal structure of a bacterial family-III cellulose-binding domain: a general mechanism for attachment to cellulose. *EMBO J.*, **15**, 5739–5751.

Wang,J.-H. and Springer,T. (1998) Structural specialization of immunoglobulin superfamily members for adhesion to integrins and viruses. *Immunol. Rev.*, **163**, 197–215.

Wann,E.R., Gurusiddappa,S. and Höök,M. (2000) The fibronectin-binding MSCRAMM FnbpA of *Staphylococcus aureus* is a bifunctional protein that also binds to fibrinogen. *J. Biol. Chem.*, **275**, 13683–13781.

Ware,S., Donahue,J.P. Hawiger,J. and Anderson,W.F. (1999) Structure of the fibrinogen γ chain integrin binding and factor XIIIa cross-linking sites obtained through carrier driven protein crystallization. *Protein Sci.*, **8**, 2663–2671.

Xiong,J.-P., Stehle,T., Diefenbach,B., Zhang,R., Dunker,R., Scott,D.L., Joachimiak,A., Goodman,S.L. and Arnaout,M.A. (2001) Crystal structure of the extracellular segment of the integrin αVβ3. *Science*, **294**, 339–345.

Received April 8, 2002; revised July 4, 2002; accepted October 1, 2002